Podcasts / Theragnostic Talks: 8. ”This is the theragnostic breakthrough” – with Oliver Sartor, Ken Hermann and Bernd Krause
Theragnostic Talks 8. ”This is the theragnostic breakthrough”

Theragnostic Talks: 8. ”This is the theragnostic breakthrough” – with Oliver Sartor, Ken Hermann and Bernd Krause

– These patients have already run a marathon, they have run through all the therapies available for them and this was their last shot. And it worked.

Listen to Dr Oliver Sartor talking about the VISION study together with Bernd Krause and Ken Hermann. They are all co-authors of the VISION study, the first international randomized open label phase III study that shows convincing results for a novel treatment of late-stage advanced prostate cancer. A targeted treatment for prostate cancer using radioactive 177Lu-PSMA-617.

– This is the first successful prospective confirmation that PET-guided patient selection is really useful, says Ken Hermann.

Bernd Krause agree:

– The VISION study was extremely important for us to promote the therapy.

The question is – are we prepared for this kind of treatment? Do we have the infrastructure? Do we need a new role for it, like theragnosticians?

Join us in this episode of Theragnostic Talks.

Guests: Oliver Sartor, Bernd Krause and Ken Hermann
By: Gustav Widar and Annette Andrén
Contact us: podcast@samnordic.se

You can also find the podcast on Google and Apple